Garry Menzel, TCR² Therapeutics CEO

TCR²'s ga­vo-cel sur­vives a PhI test. Now it's head-first in­to PhII with a half-dozen par­tial re­spons­es

A T cell biotech has some pos­i­tive re­sults, and now that the da­ta are out, the biotech is mov­ing for­ward on its next steps.

TCR² Ther­a­peu­tics teased re­sults from the Phase I por­tion of an on­go­ing Phase I/II study Tues­day, go­ing on a con­fer­ence call Wednes­day to dive more in­to the de­tails of what end­ed up hap­pen­ing. The com­pa­ny’s drug can­di­date, ga­vo-cel, is be­ing in­ves­ti­gat­ed in sol­id tu­mors ex­press­ing mesothe­lin, a pro­tein that has been ex­am­ined as a bio­mark­er in oth­er T cell ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.